腺相关病毒载体作为基因治疗传递的平台。
Adeno-associated virus vector as a platform for gene therapy delivery.
机构信息
Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA.
Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA, USA.
出版信息
Nat Rev Drug Discov. 2019 May;18(5):358-378. doi: 10.1038/s41573-019-0012-9.
Abstract
Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field. Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with two AAV-based therapeutics gaining regulatory approval in Europe or the United States. Continued study of AAV biology and increased understanding of the associated therapeutic challenges and limitations will build the foundation for future clinical success.
摘要
腺相关病毒 (AAV) 载体是治疗多种人类疾病的基因传递的主要平台。在开发临床上理想的 AAV 衣壳、优化基因组设计和利用革命性生物技术方面的最新进展，为基因治疗领域的发展做出了巨大贡献。在 AAV 介导的基因替换、基因沉默和基因编辑的临床前和临床成功，帮助 AAV 作为理想的治疗载体获得了广泛认可，有两种基于 AAV 的治疗药物在欧洲或美国获得了监管批准。对 AAV 生物学的持续研究和对相关治疗挑战和限制的深入了解，将为未来的临床成功奠定基础。
相似文献
1
Adeno-associated virus vector as a platform for gene therapy delivery.腺相关病毒载体作为基因治疗传递的平台。
Nat Rev Drug Discov. 2019 May;18(5):358-378. doi: 10.1038/s41573-019-0012-9.
2
Adeno-associated virus (AAV) vectors in cancer gene therapy.癌症基因治疗中的腺相关病毒（AAV）载体。
J Control Release. 2016 Oct 28;240:287-301. doi: 10.1016/j.jconrel.2016.01.001. Epub 2016 Jan 12.
3
Basic biology of adeno-associated virus (AAV) vectors used in gene therapy.用于基因治疗的腺相关病毒（AAV）载体的基础生物学
Curr Gene Ther. 2014;14(2):86-100. doi: 10.2174/1566523214666140302193709.
4
The state of the art of adeno-associated virus-based vectors in gene therapy.基于腺相关病毒载体的基因治疗的技术现状。
Virol J. 2007 Oct 16;4:99. doi: 10.1186/1743-422X-4-99.
5
From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.从病毒进化到载体革命：利用天然存在的腺相关病毒（AAV）血清型作为人类基因治疗的新型载体。
Curr Gene Ther. 2003 Aug;3(4):281-304. doi: 10.2174/1566523034578285.
6
Parvovirus-mediated gene transfer for the haemophilias.细小病毒介导的血友病基因转移
Haemophilia. 2002 Mar;8 Suppl 2:60-7. doi: 10.1046/j.1351-8216.2001.00121.x.
7
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.腺相关病毒（AAV）载体介导的视网膜基因递送：策略与应用
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):343-52. doi: 10.1016/j.ejpb.2015.01.009. Epub 2015 Jan 20.
8
Evolving AAV-delivered therapeutics towards ultimate cures.不断发展的 AAV 递送治疗方法以实现终极治愈。
J Mol Med (Berl). 2021 May;99(5):593-617. doi: 10.1007/s00109-020-02034-2. Epub 2021 Feb 16.
9
Adeno-Associated Virus Vector for Central Nervous System Gene Therapy.用于中枢神经系统基因治疗的腺相关病毒载体
Trends Mol Med. 2021 Jun;27(6):524-537. doi: 10.1016/j.molmed.2021.03.010. Epub 2021 Apr 21.
10
Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution.小而强大：AAV 载体研究、设计和进化的最新进展。
Hum Gene Ther. 2017 Nov;28(11):1075-1086. doi: 10.1089/hum.2017.172. Epub 2017 Aug 23.
引用本文的文献
1
Rescue of ciliogenesis and hyperglutamylation mutant phenotype in AGBL5 cell model of retinitis pigmentosa.在视网膜色素变性AGBL5细胞模型中挽救纤毛发生和高谷氨酰胺化突变体表型。
BMC Mol Cell Biol. 2025 Sep 9;26(1):27. doi: 10.1186/s12860-025-00551-x.
2
Blades and barriers: Oral vaccines for conquering cancers and warding off infectious diseases.利刃与屏障：用于攻克癌症和抵御传染病的口服疫苗
Acta Pharm Sin B. 2025 Aug;15(8):3925-3950. doi: 10.1016/j.apsb.2025.05.038. Epub 2025 Jun 3.
3
GD2T cells as a platform for single-dose and long-term delivery of biologics.GD2T细胞作为生物制剂单剂量和长期递送的平台。
Nat Commun. 2025 Aug 29;16(1):8088. doi: 10.1038/s41467-025-63427-w.
4
Applications of Tailored Mesoporous Silicate Nanomaterials in Regenerative Medicine and Theranostics.定制介孔硅酸盐纳米材料在再生医学和诊疗学中的应用。
Int J Mol Sci. 2025 Aug 16;26(16):7918. doi: 10.3390/ijms26167918.
5
Pseudovirus as an Emerging Reference Material in Molecular Diagnostics: Advancement and Perspective.假病毒作为分子诊断中新兴的参考物质：进展与展望
Curr Issues Mol Biol. 2025 Jul 29;47(8):596. doi: 10.3390/cimb47080596.
6
Programmable self-replicating JEV nanotherapeutics redefine RNA delivery in ALS.可编程的自我复制日本脑炎病毒纳米疗法重新定义了肌萎缩侧索硬化症中的RNA递送。
Commun Biol. 2025 Aug 26;8(1):1282. doi: 10.1038/s42003-025-08579-7.
7
CRISPR/Cas9 a genomic engineering technology for treatment in ALS mouse models.CRISPR/Cas9：一种用于治疗肌萎缩侧索硬化症小鼠模型的基因组编辑技术。
Regen Ther. 2025 Aug 13;30:575-583. doi: 10.1016/j.reth.2025.07.009. eCollection 2025 Dec.
8
Adeno-Associated Virus 2 (AAV2) - Induced RPA exhaustion generates cellular DNA damage and restricts viral gene expression.腺相关病毒2型（AAV2）诱导的RPA耗竭会产生细胞DNA损伤并限制病毒基因表达。
PLoS Pathog. 2025 Aug 18;21(8):e1013142. doi: 10.1371/journal.ppat.1013142. eCollection 2025 Aug.
9
AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects.腺相关病毒微小肌营养不良蛋白基因替代疗法治疗杜氏肌营养不良症：进展与前景
Gene Ther. 2025 Aug 15. doi: 10.1038/s41434-025-00561-6.
10
Viral metagenomics reveals parvovirus dark matter of herbivorous wildlife from the Qinghai-Tibet Plateau.病毒宏基因组学揭示了青藏高原食草野生动物中的细小病毒暗物质。
BMC Microbiol. 2025 Aug 15;25(1):508. doi: 10.1186/s12866-025-04281-0.
本文引用的文献
1
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses.工程化腺相关病毒载体以逃避固有免疫和炎症反应。
Sci Transl Med. 2021 Feb 10;13(580). doi: 10.1126/scitranslmed.abd3438.
2
Base editing: precision chemistry on the genome and transcriptome of living cells.碱基编辑：活细胞基因组和转录组的精准化学。
Nat Rev Genet. 2018 Dec;19(12):770-788. doi: 10.1038/s41576-018-0059-1.
3
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.用免疫耐受型雷帕霉素纳米粒有选择性地调节 AAV 免疫原性，可实现载体的再次成功给药。
Nat Commun. 2018 Oct 5;9(1):4098. doi: 10.1038/s41467-018-06621-3.
4
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy.基因编辑恢复了杜氏肌营养不良犬模型中的肌营养不良蛋白表达。
Science. 2018 Oct 5;362(6410):86-91. doi: 10.1126/science.aau1549. Epub 2018 Aug 30.
5
AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6.腺相关病毒8型和9型载体与血清蛋白的协同方式不同于腺相关病毒1型和6型。
Mol Ther Methods Clin Dev. 2018 Aug 8;10:291-302. doi: 10.1016/j.omtm.2018.08.001. eCollection 2018 Sep 21.
6
Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice.Cas9 介导的等位基因交换修复小鼠的复合杂合隐性突变。
Nat Biotechnol. 2018 Oct;36(9):839-842. doi: 10.1038/nbt.4219. Epub 2018 Aug 13.
7
Gene therapy for neurological disorders: progress and prospects.神经疾病的基因治疗：进展与前景
Nat Rev Drug Discov. 2018 Sep;17(9):641-659. doi: 10.1038/nrd.2018.110. Epub 2018 Aug 10.
8
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.系统性 AAV 微肌营养不良蛋白基因治疗杜氏肌营养不良症。
Mol Ther. 2018 Oct 3;26(10):2337-2356. doi: 10.1016/j.ymthe.2018.07.011. Epub 2018 Jul 17.
9
Accurate and Rapid Sequence Analysis of Adeno-Associated Virus Plasmids by Illumina Next-Generation Sequencing.通过Illumina下一代测序对腺相关病毒质粒进行准确快速的序列分析
Hum Gene Ther Methods. 2018 Oct;29(5):201-211. doi: 10.1089/hgtb.2018.037. Epub 2018 Aug 22.
10
Widespread anti-CRISPR proteins in virulent bacteriophages inhibit a range of Cas9 proteins.广泛存在于烈性噬菌体中的抗 CRISPR 蛋白可抑制多种 Cas9 蛋白。
Nat Commun. 2018 Jul 25;9(1):2919. doi: 10.1038/s41467-018-05092-w.
Zotero 插件